T. C. Okoro

Failure of Vedolizumab as First-Line Biologic Does Not Decrease Response Rates of Second-Line Therapy

T. Hardin, T. Ritter, L. V. Anglen, 2018, American Journal of Gastroenterology.

PROMOTING PERFORMANCE OF SMES ARCHITECTURAL FIRMS IN IMO STATE THROUGH APPLICATION OF COST ACCOUNTING SKILLS

T. C. Okoro, Miriam Chukwuma Uchegbu, Enyeribe Vivian Anuli, 2021, International Journal of Research -GRANTHAALAYAH.